The recent completion of patient enrollment in UroGen Pharma’s Phase 3 UTOPIA trial marks a major step forward in the development of UGN-103 (mitomycin) for intravesical solution under investigation for the treatment of recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). medac CDMO is proud to contribute significantly to this achievement as the development and manufacturing partner for UGN-103....

With over 25 years of aseptic manufacturing experience, medac CDMO enters the global CDMO market under a single, unified brand in 2025. This strategic rebranding brings together two GMP-certified production sites in Germany and the Czech Republic alongside the headquarters in Wedel, aligning capabilities, management and mission.

medac Group, a trusted partner in contract development and manufacturing, proudly announces the successful commissioning of its latest investment: the third production line at oncomed, a state-of-the-art production site in the Czech Republic.